Scott Evans, MD
Sports Medicine · San Diego, CANPI 1699894808
Payments from drug & device makers
Across 25 payments — averaging $107.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Johnson & Johnson$100
- Edwards Lifesciences$52
- Boston Scientific$46
- Hologic Sales And Service, LLC$38
- Neurelis, Inc.$25
- plus $219 from 11 others
Across 6 payments — averaging $1250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$5K
- AstraZeneca$2K
What the payments were for
- Consulting fees$2,20082%
- Food & beverage$48018%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $2,200 |
| Johnson & Johnson(2 entities) | 6 | $100 |
| Edwards Lifesciences | 1 | $52 |
| Boston Scientific | 1 | $46 |
| Hologic Sales And Service, LLC | 2 | $38 |
| Neurelis, Inc. | 1 | $25 |
| Seqirus USA Inc | 1 | $25 |
| Alkermes, Inc. | 1 | $23 |
| Novo Nordisk | 1 | $22 |
| AbbVie | 1 | $22 |
| Pfizer | 1 | $21 |
| GSK | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Teleflex LLC | 1 | $18 |
| Baxter Healthcare | 1 | $18 |
| Fidia Pharma USA Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
How this compares
$2,680 in reported general payments places this provider in the 50th percentile of 662 sports medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 95 | $162,119 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $56,478 |
| JardianceEmpagliflozin | 61 | $51,292 |
| EliquisApixaban | 35 | $31,199 |
| TrulicityDulaglutide | 21 | $29,282 |
| XareltoRivaroxaban | 22 | $25,105 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 33 | $6,782 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $6,317 |
| Atorvastatin Calcium | 515 | $4,191 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $2,705 |
| Levothyroxine Sodium | 285 | $2,456 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $2,109 |
| SynthroidLevothyroxine Sodium | 31 | $1,854 |
| Rosuvastatin Calcium | 170 | $1,757 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 69 | $1,659 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $22 | $162,11995 claims |
| GSKTrelegy Ellipta | $21 | $56,47862 claims |
| PfizerEliquis | $21 | $31,19935 claims |
| Johnson & JohnsonXarelto | $100 | $25,10522 claims |
| AstraZenecaSymbicort | $2,200 | $6,31711 claims |
| AbbVieSynthroid | $22 | $1,85431 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 662 sports medicine providers in California.
Other sports medicine in San Diego
- Okechukwu AnakwenzeSan Diego$623K
- Tal DavidSan Diego$523K
- Michelle LookSan Diego$225K
- Neal ElattracheLos Angeles$51M
- Nathaniel CohenLos Gatos$6.4M
- Thomas KnappSanta Monica$2.5M
- Seth ShermanStanford$1.8M
- Michael FreehillStanford$1.7M
- Deryk JonesSan Carlos$1.6M
- Allan MishraMenlo Park$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.